Released Aug 7, 2024, after the close
10-Q filed Aug 8, 2024, 39 days after period end · 0001636422-24-000120
Q2 2024 · 10-Q
Revenue$75.90M$75.90M +3.7% vs Q2 2023+1.6% vs Q1 2024
Net Income-$13.52M-$13.52M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.23-$0.23 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$15,807,000N/M
Operating Cash Flowderived$1,612,000N/M
Free Cash Flowderived$1,322,000N/M
Margins · derived
Operating margin-20.8%+26.5 pt vs Q2 2023
Net margin-17.8%+26.7 pt vs Q2 2023
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $75.90M | $73.21M | $70.63M | $59.63M |
| Net Income | -$13.52M | -$32.61M | -$33.43M | -$35.83M |
| EPS Diluted | -$0.23 | -$0.58 | -$0.62 | -$0.80 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Health Catalyst, Inc. · CIK 1636422 · Engraved from SEC EDGAR